Thursday, October 26, 2017

Researchers report why Alzheimer's drugs work in the lab but not in patients

A tremendous amount of amyloid-β peptide (Aβ) (a peptide of ~40 amino acids) accumulates in the brains of Alzheimer’s disease patients. γ-Secretase inhibitors were designed to inhibit the enzymatic activity that produces Aβ. By reducing Aβ production, γ-secretase inhibitors were able to treat Alzheimer’s disease (Aβ hypothesis). In fact, nearly 50 clinical trials have been conducted using potential γ-secretase inhibitors for Alzheimer’s disease or several types of cancer. However, all of these trials failed, except for two studies which are currently ongoing.

from Dementia Big http://ift.tt/2gElyRt via alcoholic dementia


http://ift.tt/2haIUim

1 comment:

  1. The Aβ region of APP contains a sequence of 42-43 amino acid residues, partially located in the extracellular domain and partially in the transmembrane domain of APP. Secretase Inhibitors

    ReplyDelete